<DOC>
	<DOCNO>NCT00004354</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine prevalence glucocorticoid-remediable aldosteronism ( GRA ) various hypertensive population screen risk member GRA pedigree . II . Investigate factor regulate blood pressure GRA ( environmental , genetically determine factor ) . III . Investigate renal hormonal mechanism regulate potassium homeostasis GRA . IV . Describe clinical phenotype GRA patient . V. Prospectively screen GRA-affected patient MRI angiography intracranial aneurysm .</brief_summary>
	<brief_title>Study Prevalence Clinical Phenotype Patients With Glucocorticoid-Remediable Aldosteronism</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients screen high blood pressure , suppress plasma renin activity level , low potassium level . Urine collect 24 hour period . Blood specimen collect molecular biologic evaluation presence chimeric gene diagnostic GRA . Any history cardiovascular event record .</detailed_description>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosed glucocorticoidremediable aldosteronism ( GRA ) hypertension Hypokalemia variably see Blood pressure variably elevate Elevated level aldosterone Low level plasma renin activity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>endocrine disorder</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hyperaldosteronism</keyword>
	<keyword>rare disease</keyword>
</DOC>